Closing the disease modification gap
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by dysregulated myeloid proliferation and hyperactive JAK-STAT signaling pathway. While JAK inhibitors have become standard therapies for the management of these conditions, significant challenges remain due to resistance to these medications and adverse effects such as cytopenias and infectious complications.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Evaluation of the UK Myeloma Research Alliance risk profile in…
The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant-ineligible newly diagnosed MM (TIE-NDMM) utilizing easily available clinical parameters.
Promising but preliminaryExploring the genetic spectrum of parkinsonism in Brazil.
Parkinsonism is a motor syndrome traditionally considered sporadic, but genetic factors are increasingly recognized. While next-generation sequencing (NGS) has identified pathogenic variants in Parkinson's disease (PD) and related disorders, data from admixed populations like Brazilians remain limited.
Near-term implementable findingStatus, challenges, and future directions of machine learning in the…
Despite advances in epilepsy treatment options, selecting the appropriate therapy for an individual with epilepsy is a process of trial and error. Machine learning holds the potential to support clinical decision making.
Near-term implementable findingSpatial habitat radiomics predicts tertiary lymphoid structure status…
Tertiary lymphoid structures (TLS) are spatially organized immune niches associated with therapeutic response and favorable outcomes in breast cancer (BC). However, TLS assessment currently relies on invasive tissue-based analyses, and the biological mechanisms underlying imaging-based TLS prediction remain poorly understood.